-
1
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
DOI 10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520. (Pubitemid 39315318)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.A.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
2
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
DOI 10.1056/NEJMoa040720
-
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
3
-
-
79957953692
-
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer
-
Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29:2191-2198.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2191-2198
-
-
Scher, H.I.1
Jia, X.2
Chi, K.3
-
4
-
-
84861690508
-
Randomized, double-blind, placebocontrolled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
-
Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebocontrolled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30:1534-1540.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1534-1540
-
-
Kelly, W.K.1
Halabi, S.2
Carducci, M.3
-
6
-
-
58149347705
-
Microtubule active agents: Beyond the taxane frontier
-
Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14:7167-7172.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7167-7172
-
-
Morris, P.G.1
Fornier, M.N.2
-
8
-
-
59449102526
-
Phase i and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors
-
Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723-730.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 723-730
-
-
Mita, A.C.1
Denis, L.J.2
Rowinsky, E.K.3
-
9
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
10
-
-
0032784113
-
Hydrocortisone with or without mitoxantrone in men with hormone- refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
-
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group b 9182 study. J Clin Oncol 1999; 17:2506-2513. (Pubitemid 29368252)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.8
, pp. 2506-2513
-
-
Kantoff, P.W.1
Halabi, S.2
Conaway, M.3
Picus, J.4
Kirshner, J.5
Hars, V.6
Trump, D.7
Winer, E.P.8
Vogelzang, N.J.9
-
11
-
-
8944220720
-
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
-
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14:1756-1764. (Pubitemid 26185452)
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.6
, pp. 1756-1764
-
-
Tannock, I.F.1
Osoba, D.2
Stockler, M.R.3
Ernst, D.S.4
Neville, A.J.5
Moore, M.J.6
Armitage, G.R.7
Wilson, J.J.8
Venner, P.M.9
Coppin, C.M.L.10
Murphy, K.C.11
-
12
-
-
0027487289
-
Importance of continued testicular suppression in hormone-refractory prostate cancer
-
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:2167- 2172. (Pubitemid 23332253)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.11
, pp. 2167-2172
-
-
Taylor, C.D.1
Elson, P.2
Trump, D.L.3
-
13
-
-
1842457650
-
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
-
DOI 10.1200/JCO.2004.06.037
-
Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025-1033. (Pubitemid 41095034)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.6
, pp. 1025-1033
-
-
Small, E.J.1
Halabi, S.2
Dawson, N.A.3
Stadler, W.M.4
Rini, B.I.5
Picus, J.6
Gable, P.7
Torti, F.M.8
Kaplan, E.9
Vogelzang, N.J.10
-
14
-
-
33644675811
-
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
-
DOI 10.1200/JCO.2005.03.4777
-
Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-8261. (Pubitemid 46211563)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.32
, pp. 8253-8261
-
-
Scher, H.I.1
Sawyers, C.L.2
-
15
-
-
84864003814
-
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
-
Eichholz A, Ferraldeschi R, Attard G, de Bono JS. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 2012; 360:68-75.
-
(2012)
Mol Cell Endocrinol
, vol.360
, pp. 68-75
-
-
Eichholz, A.1
Ferraldeschi, R.2
Attard, G.3
De Bono, J.S.4
-
16
-
-
0842311632
-
The Androgen Axis in Recurrent Prostate Cancer
-
DOI 10.1158/1078-0432.CCR-1146-03
-
Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10:440-448. (Pubitemid 38173980)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.2
, pp. 440-448
-
-
Mohler, J.L.1
Gregory, C.W.2
Ford III, H.3
Kim, D.4
Weaver, C.M.5
Petrusz, P.6
Wilson, E.M.7
French, F.S.8
-
17
-
-
34250331066
-
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
-
DOI 10.1158/0008-5472.CAN-06-3332
-
Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen- regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67:5033-5041. (Pubitemid 46910214)
-
(2007)
Cancer Research
, vol.67
, Issue.10
, pp. 5033-5041
-
-
Mostaghel, E.A.1
Page, S.T.2
Lin, D.W.3
Fazli, L.4
Coleman, I.M.5
True, L.D.6
Knudsen, B.7
Hess, D.L.8
Nelson, C.C.9
Matsumoto, A.M.10
Bremner, W.J.11
Gleave, M.E.12
Nelson, P.S.13
-
18
-
-
49249119358
-
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
-
Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
-
(2008)
Cancer Res
, vol.68
, pp. 4447-4454
-
-
Montgomery, R.B.1
Mostaghel, E.A.2
Vessella, R.3
-
19
-
-
0029058770
-
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer
-
Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995; 38:2463-2471.
-
(1995)
J Med Chem
, vol.38
, pp. 2463-2471
-
-
Potter, G.A.1
Barrie, S.E.2
Jarman, M.3
Rowlands, M.G.4
-
20
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005. The results of this clinical trial revealed abiraterone with prednisone to have a survival benefit over placebo and prednisone in a postdocetaxel mCRPC patient population, leading to the FDA approval of abiraterone in the USA.
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
21
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-148. The results of this clinical trial demonstrated abiraterone plus predisone improves overall survival in chemotherapy-nai?ve patients with CPRC, leading to FDA approval of expanded indication for abiraterone.
-
N Engl J Med
, vol.2013
, Issue.368
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
De Bono, J.S.3
-
22
-
-
65649090203
-
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
-
Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
-
(2009)
Science
, vol.324
, pp. 787-790
-
-
Tran, C.1
Ouk, S.2
Clegg, N.J.3
-
23
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
-
(2010)
Lancet
, vol.375
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
-
24
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197. The results of this clinical trial revealed a survival benefit of enzalutamide over placebo in patients with postdocetaxel mCRPC, leading to the recent FDA approval of enzalutamide in the USA.
-
(2012)
N Engl J Med
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
25
-
-
77956235472
-
Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer
-
Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 2010; 16:4319-4324.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4319-4324
-
-
Yamaoka, M.1
Hara, T.2
Kusaka, M.3
-
26
-
-
84860870765
-
Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration- resistant prostate cancer: Updated data from a phase I/II study
-
abstr 98
-
Agus DB, Stadler MW, Shevrin DH, et al. Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration- resistant prostate cancer: updated data from a phase I/II study. J Clin Oncol 2012; 30 (Suppl. 5):abstr. 98.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL. 5
-
-
Agus, D.B.1
Stadler, M.W.2
Shevrin, D.H.3
-
27
-
-
80054021222
-
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors
-
Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71:6503-6513.
-
(2011)
Cancer Res
, vol.71
, pp. 6503-6513
-
-
Cai, C.1
Chen, S.2
Ng, P.3
-
28
-
-
84863013857
-
Modeling a lethal prostate cancer variant with small-cell carcinoma features
-
Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012; 18:666-677.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 666-677
-
-
Tzelepi, V.1
Zhang, J.2
Lu, J.F.3
-
29
-
-
80052827038
-
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants
-
Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17:5913-5925.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5913-5925
-
-
Mostaghel, E.A.1
Marck, B.T.2
Plymate, S.R.3
-
30
-
-
79952360832
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
-
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-822.
-
(2011)
Lancet
, vol.377
, pp. 813-822
-
-
Fizazi, K.1
Carducci, M.2
Smith, M.3
-
31
-
-
0037009822
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
32
-
-
0031954325
-
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial
-
Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574-1581. (Pubitemid 28175783)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.4
, pp. 1574-1581
-
-
Serafini, A.N.1
Houston, S.J.2
Resche, I.3
Quick, D.P.4
Grund, F.M.5
Ell, P.J.6
Bertrand, A.7
Ahmann, F.R.8
Orihuela, E.9
Reid, R.H.10
Lerski, R.A.11
Collier, B.D.12
McKillop, J.H.13
Purnell, G.L.14
Pecking, A.P.15
Thomas, F.D.16
Harrison, K.A.17
-
33
-
-
0025781809
-
A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
-
Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27:954-958.
-
(1991)
Eur J Cancer
, vol.27
, pp. 954-958
-
-
Lewington, V.J.1
McEwan, A.J.2
Ackery, D.M.3
-
34
-
-
84860854128
-
Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castrationresistant prostate cancer with bone metastases
-
abstr 8
-
Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castrationresistant prostate cancer with bone metastases. J Clin Oncol 2012; 30 (Suppl. 5):abstr. 8. The results of this clinical trial [34 &, 35 & ] demonstrated significant survival benefit, at an interim analysis, along with pain palliation and excellent safety profile, based on which radium-223 chloride was granted Fast Track designation by the FDA.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL. 5
-
-
Parker, C.1
Heinrich, D.2
O'Sullivan, J.M.3
-
35
-
-
84865834363
-
Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer patients with bone metastases (ALSYMPCA)
-
Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer patients with bone metastases (ALSYMPCA). J Clin Oncol 2012; 30 (Suppl.):LBA4512. The results of this clinical trial [34 &, 35 & ] demonstrated significant survival benefit, at an interim analysis, along with pain palliation and excellent safety profile, based on which radium-223 chloride was granted Fast Track designation by the FDA.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
36
-
-
68549135290
-
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
-
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-3679.
-
(2009)
Cancer
, vol.115
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
-
37
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
38
-
-
84866562665
-
Prostate cancer, version 3.2012: Featured updates to the NCCN guidelines
-
Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 2012; 10:1081-1087.
-
(2012)
J Natl Compr Cancer Netw
, vol.10
, pp. 1081-1087
-
-
Mohler, J.L.1
Armstrong, A.J.2
Bahnson, R.R.3
-
39
-
-
80053571555
-
Cabozantinib (XL184) in metastatic castration-resistant prostate cancer: Results from a phase II randomized discontinuation trial
-
abstr 4516
-
Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer: results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29(Suppl.):abstr. 4516.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Hussain, M.1
Smith, M.R.2
Sweeney, C.3
-
40
-
-
84905170852
-
Cabozantinib (XL184) in chemotherapy- pretreated metastatic castration resistant prostate cancer: Results from a phase II nonrandomized expansion cohort
-
abstr 4513
-
Smith MR, Sweeney C, Rathkopf DE, et al. Cabozantinib (XL184) in chemotherapy- pretreated metastatic castration resistant prostate cancer: results from a phase II nonrandomized expansion cohort. J Clin Oncol 2012; 30 (Suppl.):abstr. 4513.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Smith, M.R.1
Sweeney, C.2
De, R.3
-
41
-
-
77957957234
-
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer
-
Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28:4247-4254.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4247-4254
-
-
Chi, K.N.1
Hotte, S.J.2
Yu, E.Y.3
-
42
-
-
80052468423
-
Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
-
Saad F, Hotte S, North S, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011; 17:5765-5773.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5765-5773
-
-
Saad, F.1
Hotte, S.2
North, S.3
|